The Potential Immunoregulatory Roles of Vitamin D in Neuromyelitis Optica Spectrum Disorder

被引:3
|
作者
Wu, Yifan [1 ]
Cai, Yu [1 ]
Liu, Mingyuan [2 ]
Zhu, Desheng [1 ]
Guan, Yangtai [1 ]
机构
[1] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Neurol, 127 Pujian Rd, Shanghai 200127, Peoples R China
[2] Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese Med & West, Dept Neurol, 110 Ganhe Rd, Shanghai 200437, Peoples R China
关键词
neuromyelitis optica spectrum disorder; NMOSD; vitamin D; immunoregulation; autoimmunity; MULTIPLE-SCLEROSIS PATIENTS; 4-SPECIFIC T-CELLS; D-BINDING PROTEIN; 1,25-DIHYDROXYVITAMIN D-3; CLINICAL-FEATURES; CONTROLLED-TRIAL; DISEASE COURSE; IGG PREDICTS; DOUBLE-BLIND; SUPPLEMENTATION;
D O I
10.1016/j.mscard.2020.102156
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Neuromyelitis optica spectrum disorder (NMOSD) is an autoantibody-mediated disease affecting the central nervous system (CNS). Its pathogenesis involves both innate and acquired immune reactions; specific antibody (Aquaporin-4 antibody) and inflammatory cells cause direct damage on lesion sites, while B cell-T cell interactions facilitate the demyelination. However, its etiology is still not fully understood. Vitamin D deficiency is present in numerous autoimmune diseases, including NMOSD. Evidence suggests that low vitamin D levels mayassociate with disease activity and relapse rate in NMOSD, indicating the participation in the pathogenesis of NMOSD. The immunoregulatory roles of vitamin D in both numerous autoimmune diseases and experimental autoimmune encephalomyelitis (EAE) models are increasingly recognized. Recent studies have revealed vitamin D modulation in cytokine production, immune cell development and differentiation, as well as antibody production. By enhancing an anti-inflammatory environment and suppressing the over-activated autoimmune process, vitamin D shows its potential immunoregulatory roles in NMOSD, which could possibly introduce a new therapy for NMOSD patients.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder
    Fung, Simon
    Shirley, Matt
    CNS DRUGS, 2023, 37 (04) : 363 - 370
  • [22] Inebilizumab for treatment of neuromyelitis optica spectrum disorder
    Tullman, Mark J.
    Zabeti, Aram
    Vuocolo, Scott
    Dinh, Quinn
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2021, 11 (05) : 341 - 352
  • [23] Pregnancy outcomes in neuromyelitis optica spectrum disorder
    Vishnevetsky, A.
    Levy, M.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 140 - 140
  • [24] Satralizumab in the treatment of neuromyelitis optica spectrum disorder
    Duchow, Ankelien
    Bellmann-Strobl, Judith
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2021, 11 (01) : 49 - 59
  • [25] Cyclophosphamide treatment in Neuromyelitis Optica Spectrum Disorder
    Gulluoglu, H.
    Uysal, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 798 - 798
  • [26] Urinalysis in patients with neuromyelitis optica spectrum disorder
    Chen, Z. G.
    Huang, J.
    Fan, R.
    Weng, R. H.
    Shinohara, R. T.
    Landis, J. R.
    Chen, Y.
    Jiang, Y.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 (04) : 619 - 625
  • [27] Frequency of comorbidities in Neuromyelitis Optica spectrum disorder
    Barzegar, Mahdi
    Mirmosayyeb, Omid
    Nehzat, Nasim
    Vaheb, Saeed
    Shaygannejad, Vahid
    Asgari, Nasrin
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 48
  • [28] A new era for neuromyelitis optica spectrum disorder
    Silbermann, Elizabeth
    Bourdette, Dennis
    LANCET, 2019, 394 (10206): : 1304 - 1305
  • [29] Neuromyelitis Optica Spectrum Disorder Presented with Pseudoathetosis
    Seok, Hung Youl
    Eun, Mi-Yeon
    Jang, Seong Hwa
    You, Sooyeoun
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (03) : 419 - 419
  • [30] Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder
    Simon Fung
    Matt Shirley
    CNS Drugs, 2023, 37 : 363 - 370